Proprietary radiosensitizing agents will be screened by Dartmouth University Medical School under a research agreement with the firm. Roberts will provide funding for the in vivo and in vitro screening. Two compounds are expected to go into Phase I clinicals in 1989. Roberts' lead radiosensitizer, etanidazole, is in Phase III trials in the U.S. and Europe. Roberts licensed etanidazole from the National Cancer Institute and is in agreements for the product with DuPont and Chemie Linz AG.
You may also be interested in...
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?